MD Anderson Awarded over $5.7 Million from Break through Cancer to Support AML Research

The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative research teams working to discover novel molecular targets to eradicate minimal residual disease in AML and to treat clonal hematopoiesis.